DRMA

+ Watchlist + Portfolio

Dermata Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.47
52-Week Range: $0.95 – $6.23
Market Cap: $5.55M
P/E (TTM): —
EPS (TTM): -3.94
Dividend Yield: —

Advanced Metrics

Price/Book: 1.59
PEG Ratio: —
Return on Equity: -183.89%
Return on Assets: -89.88%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.81
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-5.11M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.50M

DRMA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.65M	$4.07M	$8.20M	$2.93M
Selling, General & Admin	$4.02M	$3.97M	$4.31M	$4.84M
Operating Expenses	$9.67M	$8.04M	$12.51M	$7.77M
Operating Income	-$9.67M	-$8.04M	-$12.51M	-$7.77M
EBITDA	-$9.67M	-$8.04M	-$12.51M	-$7.77M
Pretax Income	-$9.61M	-$7.79M	-$12.29M	-$7.56M
Net Income	-$9.61M	-$7.79M	-$12.29M	-$7.56M
Diluted EPS	-2088.00	-399.90	-80.32	-8.16
Diluted Shares	4604	19492	152974	926192

DRMA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$6.24M	$7.44M	$3.16M	$7.52M
Receivables	$12.60K	$8.36K	—	—
Current Assets	$6.94M	$7.98M	$3.53M	$7.86M
Total Assets	$6.94M	$7.98M	$3.53M	$7.86M
Current Liabilities	$922.63K	$1.62M	$1.97M	$1.64M
Total Liabilities	$922.63K	$1.62M	$1.97M	$1.64M
Retained Earnings	-$45.59M	-$53.39M	-$65.68M	-$73.23M
Shareholders' Equity	$6.02M	$6.36M	$1.56M	$6.22M
Working Capital	$6.02M	$6.36M	$1.56M	$6.22M

DRMA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$8.83M	-$6.41M	-$11.16M	-$7.76M
Free Cash Flow	-$8.83M	-$6.41M	-$11.16M	-$7.76M
Stock-Based Compensation	$930.33K	$522.08K	$657.65K	$143.73K
Financing Cash Flow	$4.28M	$7.61M	$6.89M	$12.12M
Share Repurchases	$0.00	-$40.00	-$828.00	-$367.00
Net Change in Cash	-$4.56M	$1.20M	-$4.28M	$4.36M

DRMA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.28M	$617.84K	$504.39K	$526.62K	$383.72K
Selling, General & Admin	$1.06M	$1.15M	$1.26M	$1.37M	$1.54M
Operating Expenses	$2.34M	$1.77M	$1.76M	$1.90M	$1.93M
Operating Income	-$2.34M	-$1.77M	-$1.76M	-$1.90M	-$1.93M
EBITDA	-$2.34M	-$1.77M	-$1.76M	-$1.90M	-$1.93M
Pretax Income	-$2.30M	-$1.70M	-$1.69M	-$1.86M	-$1.85M
Net Income	-$2.30M	-$1.70M	-$1.69M	-$1.86M	-$1.85M
Diluted EPS	-4.47	-1.66	-1.65	—	-0.48
Diluted Shares	515465	1.03M	1.03M	—	3.86M

DRMA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$9.72M	$6.48M	$4.66M	$7.52M	$6.95M
Inventory	—	—	—	—	$93.09K
Current Assets	$10.01M	$6.64M	$5.07M	$7.86M	$7.47M
Total Assets	$10.01M	$6.64M	$5.07M	$7.86M	$7.47M
Current Liabilities	$2.70M	$1.03M	$1.11M	$1.64M	$1.05M
Total Liabilities	$2.70M	$1.03M	$1.11M	$1.64M	$1.05M
Retained Earnings	-$67.98M	-$69.68M	-$71.37M	-$73.23M	-$75.08M
Shareholders' Equity	$7.30M	$5.61M	$3.96M	$6.22M	$6.41M
Working Capital	$7.30M	$5.61M	$3.96M	$6.22M	$6.41M

DRMA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.93M	-$2.69M	-$1.80M	-$1.33M	-$2.48M
Free Cash Flow	-$1.93M	-$2.69M	-$1.80M	-$1.33M	-$2.48M
Stock-Based Compensation	$37.19K	$39.23K	$37.84K	$29.47K	$43.28K
Financing Cash Flow	$8.49M	-$547.86K	-$12.99K	$4.19M	$1.90M
Share Repurchases	—	—	-$367.00	$0.00	—
Net Change in Cash	$6.56M	-$3.24M	-$1.82M	$2.86M	-$576.70K

Market Snapshot

About

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing treatments for dermatological and connective tissue diseases. The company's lead program targets medical and aesthetic skin conditions using novel small molecule therapeutics. Dermata is developing treatments for conditions including psoriasis, acne, rosacea, and keloid scarring. The company utilizes its proprietary understanding of skin biology and inflammation pathways to develop differentiated therapies. Dermata's pipeline includes both prescription pharmaceutical candidates and potential over-the-counter products.